# Curatio Healthcare Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curatio-healthcare-private

- Industry: Healthcare Specialists
- Headquarters: Chennai, India
- Website: www.curatiohealthcare.com
- Total disclosed funding: $1.9M
- Latest round: Seed (Jun 1, 2005)
- Investors on record: 1

## About

Curatio Healthcare Private Limited specializes in providing innovative healthcare solutions and products, focusing on enhancing dermatological care and addressing varied consumer health needs.Founded in 2005 and headquartered in Chennai, India, Curatio Healthcare Private Limited develops and markets healthcare products, particularly in dermatology. The company was acquired by Torrent Pharmaceuticals Ltd. in September 2022 for INR 20 billion, enhancing Torrent's dermatology presence. K R Krishna is the founder, who has a background in establishing healthcare-related ventures. Curatio Healthcare has completed a total of six deals, with the most recent transaction occurring in September 2022.Curatio Healthcare offers a diverse range of products aimed at various healthcare sectors, focusing on dermatological solutions. Their offerings include advanced technology solutions that enhance operational efficiency, alongside consumer products designed for everyday health challenges. The company's client base spans globally, with significant presence in North America and Europe, while also targeting emerging markets in the Asia-Pacific region. Their products are utilized by both enterprises and individual consumers seeking effective healthcare solutions.In the most recent fiscal year 2022, Curatio Healthcare reported a revenue of INR 30,628,646.70 and an EBITDA of INR 8,124,453.80. The company's revenue model is primarily based on B2B partnerships and direct sales to consumers, utilizing a mix of subscription-based services and one-time product purchases, ensuring a broad customer reach and sustained revenue streams.Curatio Healthcare intends to leverage its recent acquisition by Torrent Pharmaceuticals to expand its product offerings, particularly in the dermatology market. There are plans for the launch of new dermatological products, aimed at addressing unique consumer needs, although specific release dates have yet to be confirmed. The company also aims to broaden its market presence, particularly targeting new segments in the Asia-Pacific region by 2025. The recent funding from the acquisition will support these expansion initiatives, facilitating investment in R&D and marketing efforts.

## Funding rounds

- Seed, Jun 1, 2005, $1.9M — Fulcrum

## Investors

- Fulcrum (https://capitalatlas.ai/funds/fulcrum) — Seed